Authors
Latest:
Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple MyelomaFaiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.
Latest:
Dr Malalur on Addressing Unmet Needs in Pancreatic CancerPannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Dr. Kumar on Immunotherapy Combinations in RCCRohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.
Latest:
UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research ForwardThe use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.
Latest:
Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCCMonica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.
Latest:
Unprecedented Advances Fuel Progress in the Treatment of AL AmyloidosisLight-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.
Latest:
Dr. Cooper on Leveraging Novel Agents and Combos in Multiple MyelomaDennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.
Latest:
The Investigational Pipeline for Advanced BTCMilind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.
Latest:
Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple MyelomaSundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.
Latest:
Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate CancerAshutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.
Latest:
Media Training Helps Investigators, Institutions ShineHere are 5 tips and tricks to help you shine when the spotlight is on you.
Latest:
Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in LeiomyosarcomaAlbiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.
Latest:
Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI CancersRachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.
Latest:
Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer SusceptibilityAndreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.
Latest:
Unmet Needs in the Management of Advanced RCCDrs Alter and Diamond muse about the unmet needs in advanced RCC treatment.
Latest:
Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLLJohn N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.
Latest:
Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLCSheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.
Latest:
Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple MyelomaSuzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Das on the Results of a Clinical Score Analysis in Patients With NETsSatya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.
Latest:
Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NECMartin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Latest:
Dr. de Marinis on the PERLA Trial in Metastatic NSCLCFilippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.
Latest:
Superagonists Pull IL-15 Into Focus in Oncology CareFollowing in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.
Latest:
Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic MalignanciesAlice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.
Latest:
Women in Oncology: Lessons to Tell Up-and-Coming Female OncologistsLaura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black WomenAdana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.
Latest:
Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer CareAnthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Key Takeaways in HER2-Mutated NSCLCThe panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Latest:
Advice For Providers Caring for Patients With HR+/HER2- mBCVirginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.
